Evidence map›Paper›PMID 27843321›Full record

ArticleNeuropsychiatric disease and treatment2016

Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies.

Yu Han, Jianjun Chen, Dezhi Zou, Peng Zheng, Qi Li, Haiyang Wang, Pengfei Li, Xinyu Zhou, Yuqing Zhang, Yiyun Liu and 1 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuropsychiatric disease and treatment, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03473431 (A Pilot Study of a Single Infusion of Ketamine in Relief of Depressive Symptoms of Elderly Patients With Visual Impairment.), which is not on this map. Cited by 50 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 10 pooled it
8.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03473431 nacompletednot on this mapstarted 2018, after this paper: background citation

A Pilot Study of a Single Infusion of Ketamine in Relief of Depressive Symptoms of Elderly Patients With Visual Impairment.

TypeinterventionalSponsorInstituto Mexicano del Seguro SocialRan2018 to 2018Enrolled90ConditionsDepression in Old Age, KetamineArmsKetamine, control
3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 10 syntheses or guidelines pooled it, 113 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Intravenous arketamine for treatment-resistant depression: open-label pilot study.European archives of psychiatry and clinical neuroscience · 2021
    Trial
  14. Trial
  15. Trial
  16. Rapid-acting NMDA and GABAergic Modulators in Mood Disorders: From Synaptic Mechanisms to Clinical Practice.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2025
    Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Yu HanDepartment of Neurology, The First Affiliated Hospital of Chongqing Medical University; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science; Chongqing Key Laboratory of Neurobiology.
Jianjun ChenInstitute of Neuroscience and the Collaborative Innovation Center for Brain Science; Chongqing Key Laboratory of Neurobiology; Institute of Life Sciences, Chongqing Medical University, Chongqing, People's Republic of China.
Dezhi ZouDepartment of Neurology, The First Affiliated Hospital of Chongqing Medical University; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science; Chongqing Key Laboratory of Neurobiology.
Peng ZhengDepartment of Neurology, The First Affiliated Hospital of Chongqing Medical University; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science; Chongqing Key Laboratory of Neurobiology.
Qi LiDepartment of Neurology, The First Affiliated Hospital of Chongqing Medical University; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science; Chongqing Key Laboratory of Neurobiology.
Haiyang WangDepartment of Neurology, The First Affiliated Hospital of Chongqing Medical University; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science; Chongqing Key Laboratory of Neurobiology.
Pengfei LiDepartment of Neurology, The First Affiliated Hospital of Chongqing Medical University; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science; Chongqing Key Laboratory of Neurobiology.
Xinyu ZhouDepartment of Neurology, The First Affiliated Hospital of Chongqing Medical University; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science; Chongqing Key Laboratory of Neurobiology.
Yuqing ZhangDepartment of Neurology, The First Affiliated Hospital of Chongqing Medical University; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science; Chongqing Key Laboratory of Neurobiology.
Yiyun LiuDepartment of Neurology, The First Affiliated Hospital of Chongqing Medical University; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science; Chongqing Key Laboratory of Neurobiology.
Peng XieDepartment of Neurology, The First Affiliated Hospital of Chongqing Medical University; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science; Chongqing Key Laboratory of Neurobiology.
The Affiliated Yongchuan Hospital of Chongqing Medical University · CNChongqing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAn increasing number of studies are reporting that ketamine could be treated as a novel antidepressant for major depressive disorder (MDD). Therefore, we performed this meta-analysis to comprehensively and systematically assess the efficacy of ketamine for treating patients with MDD.

methodRandomized, double-blind, placebo-controlled studies on ketamine versus placebo for treating MDD were searched up to April 2016 in medical databases (PubMed, CCTR, Web of Science, Embase, CBM-disc, and CNKI). Three treatment time points (24 and 72 h, and day 7) were chosen. Response and remission rates were the main outcomes. The random effects model was used. An intention-to-treat analysis was conducted.

resultsNine high-quality studies that included 368 patients were selected to compare the efficacy of ketamine to placebo. The therapeutic effects of ketamine at 24 and 72 h, and day 7 were found to be significantly better than placebo. Response and remission rates in the ketamine group at 24 and 72 h, and day 7 were 52.2% and 20.6%; 47.9% and 23.8%; and 39.8% and 26.2%, respectively. No significant heterogeneity existed, and the Egger's test showed no publication bias.

conclusionThese results indicated that ketamine could yield a good efficacy in the rapid treatment of MDD. Future large-scale clinical studies are needed to confirm our results and investigate the mid- and long-term efficacy of ketamine in treating MDD.

Indexed as

ketaminemajor depressive disorderMDDmeta-analysis

Identifiers

PMID27843321
PMCPMC5098773
OpenAlexW2548304375

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.